my article on childhood viral respiratory diseases is now out @RoyalSocBiorsb.org.uk/biologist-feat… (delighted to be sandwiched in between a piece on oxylipins and another on latent lepidopterans)🧵
I look at why lockdown wasn't associated with a decrease in childhood deaths, despite a fall in infections
with RSV vaccines on the horizon, and a massive research infrastructure in place for SARS-CoV-2 eurosurveillance.org/content/10.280…
we should leverage this once/if we ever work out how to live with COVID-19
and work out how to make the two current most common diagnoses of infancy and early childhood, bronchiolitis and viral wheeze, diseases of the past polioeradication.org/polio-today/hi… (END)
• • •
Missing some Tweet in this thread? You can try to
force a refresh
While the rest of the world deliberates about the logistics of introducing maternal immunisation against RSV, or nirsevimab (a long lasting anti-RSV monoclonal antibody)
Galicia in NW Spain has cracked on with giving nirsevimab to all newborns
What is really impressive ... 1/n
is their commitment to releasing their data in near real-time. You can read their latest report from two days ago here:
Report_RSV_week47.pdf () 2/n sergas.es
My two take home messages from the report: 1. Uptake for nirsevimab was very high- we should make sure we learn from the Galicians how they encouraged parents/carers to decide to protect their newborn infants against RSV 3/n
our paper from the @WHO RSV Surveillance Laboratory Group is now out in the @IsirvEpi journal onlinelibrary.wiley.com/doi/full/10.11…
impressive results for the detection and typing of RSV using RT-PCR from 26 National @WHO collaborating centres globally 1/4
whole genome sequences for the strains used in this External Quality Assessment conducted by @UKNEQAS available @GISAID 2/4
with RSV immunisations edging close and closer, more and more important to accurately detect and quantify the burden of disease as a baseline prior to introduction 3/4
huge amount of recent interest in invasive group A streptococcus (iGAS) infection in children
but up until now little patient-level clinical data on this spike in cases
we hope our case series @TheLancetInfDis will help address this knowledge gap thelancet.com/journals/lanin… 1/n
back in the autumn a group of us at the Royal Hospital for Children in Glasgow noticed a spike in empyema cases in children
in Nov 23 alone we looked after 9 children with empyema requiring a chest drain, almost as many as we'd expect to see in an entire year at our centre 2/n
Scotland is a small country so we reached out to our colleagues in other centres that manage paediatric empyema (pus in the chest cavity) in Edinburgh and Aberdeen to see if they were experiencing a similar phenomenon 3/n
but price is going to be key: how much these interventions costs will determine how widely they are used 6/n
another important question is whether it is going to be possible to interrupt community transmission for RSV with a vaccine for infants
the PHIRST study was designed to look at this pubmed.ncbi.nlm.nih.gov/34019838/ for influenza, RSV and later on adapted for SARS-CoV-2 7/n
unpublished results for RSV presented today show similarly high burden of disease 8/n
now @rsv2022 Prof. Cheryl Cohen @WitsUniversity talks about key considerations in implementing an RSV vaccine 1/n
these are:
-burden of disease
--in relation to other vaccine preventable disease
--age specific burden
--different severity endpoints
--seasonality
-cost of disease
-cost-effectiveness
-risk groups for severe illness
-pathogen factors
-transmission dynamics- indirect effects 2/n
key to implementation will be age distribution of disease: both monoclonals and maternal immunisation will only prevent disease for a time-limited period 3/n